Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27040991 | 1.00 | CHRM2 (0.48) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL27040994 | 1.00 | CHRM2 (0.48) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL17199602 | 0.89 | ALDH1A1 (0.40) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL22587586 | 0.84 | ALDH1A1 (0.50) | GPR119ALDH1A1LMNAMAPTDDB1 | |
| SCHEMBL1558660 | 0.83 | DDB1 (0.52) | GPR119ALDH1A1LMNAMAPTDDB1 | |
| SCHEMBL16423801 | 0.82 | ALDH1A1 (0.47) | GPR119ALDH1A1LMNAMAPTDDB1 | |
| SCHEMBL11946808 | 0.82 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL29548109 | 0.82 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL26865491 | 0.82 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL15709870 | 0.82 | F2 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | CHRM2 2286/4885CHRM1 1705/4885CHRM3 1891/4885 |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | CHRM2 2534/4885CHRM1 1920/4885CHRM3 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.